Skip to main
CRBU

Caribou Biosciences (CRBU) Stock Forecast & Price Target

Caribou Biosciences (CRBU) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Caribou Biosciences is showing strong financial performance, reporting a narrower net loss of $0.26 per share for Q1 2026 compared to analyst estimates of $0.32 per share. With a projected full-year net loss of $1.23 per share and a strong cash balance of $118.6 million, the company is well-positioned for future growth and has a strong runway into 2027. The positive outlook is reflected in the Buy rating and raised price target of $11 per share, indicating confidence in the company's potential for success.

Bears say

Caribou Biosciences is facing significant challenges with its clinical trials for Vispacabtagene regedleucel and CB-011, with potentially disappointing results from longer follow-up on the ANTLER trial and initial dose expansion results for CB-011. This may lead to delays in its product pipeline and impact revenue growth in the short-term, making it a risky investment for potential investors. Additionally, the company's concentration in the US market for revenue generation adds further uncertainty to its future financial performance.

Caribou Biosciences (CRBU) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Caribou Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Caribou Biosciences (CRBU) Forecast

Analysts have given Caribou Biosciences (CRBU) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Caribou Biosciences (CRBU) has a Strong Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Caribou Biosciences (CRBU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.